Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Avutometinib · Avmapki Fakzynja Co-Pack, VS-6766

Small molecule · Inhibitor of MEK1/2 (MAP2K1/MAP2K2) (MAP2K1) and RAF kinases (RAF1) · developed by Verastem

Approved FDA
VSTM Developer
9 Registered trials

What is Avutometinib?

Avutometinib is an orally bioavailable inhibitor of the RAF and MEK kinases in the RAS/RAF/MEK/ERK (MAPK) pathway. It induces inactive RAF/MEK complexes that block MEK1/2 phosphorylation and ERK signaling in tumor cells with KRAS mutations. It is studied in ovarian, lung, breast, pancreatic, colorectal and uveal melanoma cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Avmapki Fakzynja Co-Pack, VS-6766, CH-5126766, CKI-27
Drug type
Small molecule
Targets
MEK1/2 (MAP2K1/MAP2K2) (MAP2K1), RAF kinases (RAF1), focal adhesion kinase (PTK2) (biomarker)
Mechanism
Inhibitor of MEK1/2 (MAP2K1/MAP2K2) (MAP2K1) and RAF kinases (RAF1)
Pathways
RAS/RAF/MEK/ERK (MAPK) pathway, FAK signaling
Therapy area
Oncology
Developer
Verastem Inc. (VSTM)
FDA status
Approved as Avmapki Fakzynja Co-Pack, NDA219616 · FDA label
UNII
D0D4252V97

✅ FDA-approved uses

From the indications section of the FDA label (version of May 1, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06072781 Phase 3 Low Grade Serous Ovarian Cancer Recruiting VSTM
NCT07747506 Phase 2 Low Grade Ovarian Serous Adenocarcinoma Not yet recruiting VSTM
NCT05669482 Phase 1/2 KRAS Activating Mutation Active not recruiting VSTM
NCT05608252 Phase 1/2 Breast Cancer Recruiting VSTM
NCT05200442 Phase 1/2 Colorectal Cancer Suspended VSTM
NCT05375994 Phase 1/2 Non Small Cell Lung Cancer Completed VSTM
NCT05074810 Phase 1/2 Non Small Cell Lung Cancer Active not recruiting VSTM
NCT04720417 Phase 2 Metastatic Uveal Melanoma Terminated VSTM
NCT04625270 Phase 2 Low Grade Ovarian Serous Adenocarcinoma Active not recruiting VSTM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerHormone Receptor-positive Breast CancerKRAS Activating MutationLow Grade Ovarian Serous AdenocarcinomaLow Grade Serous Ovarian CancerMalignant Neoplasm of PancreasNeoplasms PancreaticNon Small Cell Lung CancerOvarian CancerPancreas CancerAdvanced CancerAdvanced Colorectal AdenocarcinomaAdvanced Colorectal Carcinoma

Other drugs acting on MAP2K1 / RAF1

More from Verastem

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VSTM page.

Follow VSTM, the company behind Avutometinib

See VSTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VSTM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.